BioTuesdays

Category - Markets

Kiadis Pharma
Markets

Roth starts Kiadis Pharma at buy

Roth Capital Partners has initiated coverage of Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) with a “buy” rating and price target of €17. The stock closed at €11.32 on Wednesday. “We believe Kiadis Pharma...

September 22, 2016
OncoMed
Markets

HCW starts OncoMed Pharma at buy

H.C. Wainwright has launched coverage of OncoMed Pharmaceuticals (NASDAQ:OMED) with a “buy” rating and $20 price target. The stock closed at $11.87 on Wednesday. “We believe OncoMed is entering a year of dramatic...

September 22, 2016
Fate Therapeutics
Markets

Roth starts Fate Therapeutics at buy

Roth Capital Partners has launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and a target price of $8. The stock closed at $3.18 on Wednesday. Analyst Mark Breidenbach writes that the...

September 22, 2016
Proteon Therapeutics
Markets

HCW starts Proteon Therapeutics at buy

H.C. Wainwright has initiated coverage of Proteon Therapeutics (NASDAQ:PRTO) with a ‘buy” rating and $18 price target. The stock closed at $8.75 on Wednesday. Proteon is developing a novel therapy to help prolong...

September 22, 2016
Bionomics
Markets

Roth ups Bionomics price target to A$2.50

Roth Capital Partners raised its price target for Bionomics (ASE:BNO; OTCQX:BNOEF) to (Australian) $2.50 from $1.50 after the company’s Phase 2 BNC210 trial met its primary and secondary endpoints in treating...

September 21, 2016
Aviragen
Markets

Ladenburg starts Aviragen Therapeutics at buy

Ladenburg Thalmann has launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and $2.50 price target. The stock closed at $1.60 on Tuesday. “We view Aviragen as an emerging small molecule antiviral...

September 21, 2016
Titan Medical
Markets

Titan Medical closes $10.25-million public offering

Titan Medical (TSX:TMD; OTCQX:TITXF) has closed a public offering of 17,083,333 units at a price of 60 cents apiece for gross proceeds of $10.25-million. Each unit consists of one common share and one warrant, which...

September 20, 2016
Recro Pharma
Markets

Roth starts Recro Pharma at buy

Roth Capital Partners has launched coverage of Recro Pharma (NASDAQ:REPH) with a “buy” rating and a $24 price target. The stock closed at $9.31 on Thursday. “The impetus for our buy rating on Recro shares is the upside...

September 16, 2016
Summit
Markets

Wainwright starts Summit Therapeutics at buy

H.C. Wainwright initiated coverage of Summit Therapeutics (NASDAQ:SMMT) with a “buy” rating and $26 price target. The stock closed at $5.50 on Thursday. Summit has two de-risked assets, with billion-dollar potential...

September 16, 2016